From MD Magazine… In just a short decade of Gregory Day’s young career, the US multiple sclerosis (MS) therapy market has exploded from just a handful options to 17 US Food and Drug Administration (FDA)-approved agents for multiple mechanisms. Day, MD, MSc, assistant professor, Washington University School of Medicine, Knight Alzheimer Disease Research Center, St. […]